deferoxamine has been researched along with Anemia With Multinucleated Erythroblasts in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine was given subcutaneously for 14 months." | 5.26 | Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I. ( Perrault, J; Smithson, WA, 1982) |
| "Iron overload was a frequent complication." | 2.42 | Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. ( Anselstetter, V; Chrobak, L; Denecke, J; Einsiedler, B; Gallmeier, K; Griesshammer, A; Heimpel, H; Janka-Schaub, G; Kohne, E; Kron, M; Marquardt, T, 2003) |
| "Deferoxamine was given subcutaneously for 14 months." | 1.26 | Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I. ( Perrault, J; Smithson, WA, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergmann, AK | 1 |
| Tamary, H | 1 |
| Neufeld, EJ | 1 |
| Cario, H | 1 |
| Grosse, R | 1 |
| Janssen, G | 1 |
| Jarisch, A | 1 |
| Meerpohl, J | 1 |
| Strauss, G | 1 |
| Buchbinder, D | 1 |
| Nugent, D | 1 |
| Vu, D | 1 |
| Soni, A | 1 |
| Stites, J | 1 |
| Hsieh, L | 1 |
| Puthenveetil, G | 1 |
| Heimpel, H | 1 |
| Anselstetter, V | 1 |
| Chrobak, L | 1 |
| Denecke, J | 1 |
| Einsiedler, B | 1 |
| Gallmeier, K | 1 |
| Griesshammer, A | 1 |
| Marquardt, T | 1 |
| Janka-Schaub, G | 1 |
| Kron, M | 1 |
| Kohne, E | 1 |
| Smithson, WA | 1 |
| Perrault, J | 1 |
| Adams, DM | 1 |
| Schultz, WH | 1 |
| Ware, RE | 1 |
| Kinney, TR | 1 |
| Galacteros, F | 1 |
| Schmitt, K | 1 |
| Tulzer, W | 1 |
| Prasher, N | 1 |
| Prasher, BS | 1 |
| Cacciola, E | 1 |
| Miyazawa, K | 1 |
| Yoshikawa, O | 1 |
| Takakuwa, Y | 1 |
| Tuda, A | 1 |
| Ohtaka, M | 1 |
| Lin, KY | 1 |
| Iguchi, Y | 1 |
| Naruto, M | 1 |
| Kondo, M | 1 |
| Toyama, K | 1 |
3 reviews available for deferoxamine and Anemia With Multinucleated Erythroblasts
| Article | Year |
|---|---|
Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation.
Topics: Adolescent; Adult; Aged; Anemia, Dyserythropoietic, Congenital; Child; Child, Preschool; Cholelithia | 2003 |
[Secondary iron overload].
Topics: Adult; Anemia, Dyserythropoietic, Congenital; Anemia, Hemolytic; Bone Marrow Examination; Chelating | 1998 |
[Successful treatment of congenital dyserythropoietic anemia type I with long-term administration of deferoxamine].
Topics: Adult; Anemia, Dyserythropoietic, Congenital; Anemia, Hemolytic, Congenital; Deferoxamine; Drug Eval | 1988 |
8 other studies available for deferoxamine and Anemia With Multinucleated Erythroblasts
| Article | Year |
|---|---|
Remission from transfusion-dependence in a patient with congenital dyserythropoietic anemia (CDA) and increased intensity of iron chelation.
Topics: Adolescent; Anemia, Dyserythropoietic, Congenital; Blood Transfusion; Deferoxamine; Erythropoiesis; | 2009 |
[Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].
Topics: Anemia, Aplastic; Anemia, Diamond-Blackfan; Anemia, Dyserythropoietic, Congenital; Anemia, Sickle Ce | 2010 |
Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload.
Topics: Anemia, Dyserythropoietic, Congenital; Benzoates; Bone Marrow Transplantation; Child, Preschool; Def | 2012 |
Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I.
Topics: Anemia, Dyserythropoietic, Congenital; Anemia, Hemolytic, Congenital; Biopsy; Child; Deferoxamine; F | 1982 |
Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients.
Topics: Adolescent; Adult; Anemia, Dyserythropoietic, Congenital; Anemia, Sickle Cell; Chelation Therapy; Ch | 1996 |
[Rare indications for iron chelation therapy with desferrioxamine].
Topics: Adolescent; Anemia, Dyserythropoietic, Congenital; Chelation Therapy; Deferoxamine; Dose-Response Re | 1991 |
Congenital dyserythropoietic anaemia.
Topics: Anemia, Dyserythropoietic, Congenital; Deferoxamine; Female; Humans | 1990 |
[Dyserythropoietic syndromes: incidence, diagnosis, therapy].
Topics: Anemia, Dyserythropoietic, Congenital; Anemia, Refractory; Anemia, Sideroblastic; Deferoxamine; Diag | 1990 |